Irinotecan (CPT-11) induced colitis: report of a case and review of Food and Drug Administration MEDWATCH reporting.
Sears
S
S
Department of Medicine, Gastroenterology, and Oncology Service, Eisenhower Army Medical Center, Augusta, Georgia, USA.
McNally
P
P
Bachinski
M S
MS
Avery
R
R
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D016907:Adverse Drug Reaction Reporting Systems; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D017024:Chemotherapy, Adjuvant; D003092:Colitis / Q000139:chemically induced* / Q000473:pathology; D003113:Colonoscopy; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000473:pathology; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D008875:Middle Aged; D009367:Neoplasm Staging; D012811:Sigmoid Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014481:United States; D014486:United States Food and Drug Administration
D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D002166:Camptothecin